Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAT-Trial: CGRP Monoclonal Antibody for Treatment of Painful Diabetic Neuropathy: a Double-blind, Randomized, Placebo-controlled, International Multicenter, Phase II Clinical Trial

Next Previous
Trial Profile

CAT-Trial: CGRP Monoclonal Antibody for Treatment of Painful Diabetic Neuropathy: a Double-blind, Randomized, Placebo-controlled, International Multicenter, Phase II Clinical Trial

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptinezumab (Primary) ; Sodium chloride
  • Indications Diabetic nephropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Acronyms CAT

Most Recent Events

  • 16 Jul 2026 This trial has been completed in Denmark
  • 06 Mar 2025 Status changed from recruiting to withdrawn prior to enrolment as no participants enrolled
  • 07 Jan 2025 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top